Skip to main content
Equibles
AUTL logo

AUTL · Autolus Therapeutics plc · Earnings Call Transcripts & Audio

Track AUTL — free

Use AUTL with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AUTL.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.92 -0.03 (-1.29%)
Rebalance outlook locked
Market Cap
$493.73M
Shares
266.16M
Volume · Oct 1 887.93K Avg daily vol (3M) 2.04M

Autolus Therapeutics plc Earnings Call Transcripts

Quarterly earnings calls for Autolus Therapeutics plc (AUTL), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
· $10.09M −$52.69M '24 Q1 24-05-17 · $ −$58.27M '24 Q2 24-08-08 · $ −$82.09M '24 Q3 24-11-12 · $29,000 −$27.61M '24 Q4 25-03-20 ▼11% $8.98M −$70.16M '25 Q1 25-05-08 · $20.92M −$47.92M '25 Q2 25-08-12 · $21.19M −$79.12M '25 Q3 25-11-12 ▲83655.2% $24.29M −$90.33M '25 Q4 26-03-27 ▲191.9% $26.22M −$71.60M '26 Q1 26-05-14 LATEST ▲118.4% $45.69M −$39.11M '26 Q2 26-08-11
Earnings call
FY26 · Q2
2026-08-11
Autolus Therapeutics plc (AUTL) Q2 2026 Earnings Call
Revenue
$45.69M
▲ 118.4% YoY
Diluted EPS
$-0.15
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-30
Autolus Therapeutics plc (AUTL) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-06-30
Autolus Therapeutics plc (AUTL) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-06-03
Autolus Therapeutics plc (AUTL) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-06-03
Autolus Therapeutics plc (AUTL) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-06-02
Autolus Therapeutics plc (AUTL) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-06-02
Autolus Therapeutics plc (AUTL) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-14
Autolus Therapeutics plc (AUTL) Q1 2026 Earnings Call Transcript
Confident tone Commercial launch of Ocastle Gross margin improvement Revenue and full-year guidance
Revenue
$26.22M
▲ 191.9% YoY
Diluted EPS
$-0.27
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-27
Autolus Therapeutics plc (AUTL) Q4 2025 Earnings Call Transcript
Confident tone Pipeline expansion (OB-Cell, Catalyst, Carlyle, Lumina) Safety/efficacy in real-world setting ROCCA real-world data consortium
Revenue
$24.29M*
▲ 83655.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-12
Autolus Therapeutics plc (AUTL) Q3 2025 Earnings Call Transcript
Confident tone Obe-cel U.S. Commercial Launch Market Share Growth in ALL Q4 and 2026 Outlook
Revenue
$21.19M
Diluted EPS
$-0.30
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-12
Autolus Therapeutics plc (AUTL) Q2 2025 Earnings Call Transcript
Positive tone Obe-cel regulatory and EU/UK market access Obe-cel US commercial launch Pipeline expansion (pediatric ALL, autoimmune)
Revenue
$20.92M
Diluted EPS
$-0.18
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Autolus Therapeutics plc (AUTL) Q1 2025 Earnings Call Transcript
Confident tone Commercial launch of AUCATZYL Pipeline expansion into lupus and other indications Manufacturing and dosing variability risk
Revenue
$8.98M
▼ 11% YoY
Diluted EPS
$-0.26
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-20
Autolus Therapeutics plc (AUTL) Q4 2024 Earnings Call Transcript
Confident tone AUCATZYL U.S. commercial launch CARLYSLE autoimmune study Center onboarding and patient access expansion
Revenue
$29,000*
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Autolus Therapeutics plc (AUTL) Q3 2024 Earnings Call Transcript
Confident tone AUCATZYL FDA approval and launch readiness Pipeline data presentations at ASH SLE and pediatric pipeline expansion
Revenue
$
Diluted EPS
$-0.31
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Autolus Therapeutics plc (AUTL) Q2 2024 Earnings Call
Revenue
$
Diluted EPS
$-0.22
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-17
Autolus Therapeutics plc (AUTL) Q1 2024 Earnings Call Transcript
Confident tone Obe-cel regulatory progress and PDUFA Pipeline expansion into autoimmune (SLE) FELIX study results and persistence/disease burden
Revenue
$10.09M
Diluted EPS
$-0.24
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-14
Autolus Therapeutics plc (AUTL) Q4 2023 Earnings Call Transcript
Confident tone FELIX study clinical data Pipeline expansion into autoimmune obe-cel BLA review and regulatory progress
Results not yet reported
Audio Transcript Slides 8-K10-K
Showing 1–17 of 17 earnings calls
Key facts CIK 1730463 CUSIP 05280R100 13F (30d) 4 filings 4 filers Visit website Investor relations